Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Merck Ignites Firework of Research Initiatives During its 350th Anniversary Year

Funding of up to € 350,000 per research grant or up to € 30,000 per research challenge

23-May-2018 - Merck announced several research grants and challenges during the company’s 350th anniversary year in addition to already existing initiatives. The new research grants and challenges are mainly directed to scientists working in institutes, universities or start-up companies around the world. “The ...

Merck Submits European Marketing Authorization Application for Sapropterin as a Treatment for Hyperphenylalaninemia

Sapropterin has been granted Orphan Medicinal Product designation for the treatment of hyperphenylalaninemia

12-Nov-2007 - Merck KGaA announced that its division Merck Serono has submitted an application to the European Medicines Agency (EMEA) for the marketing authorization (MA) of sapropterin (INN: sapropterin dihydrochloride, formerly known as Phenoptin(TM)) as an oral treatment for significant ...

Merck KGaA restructured its pharmaceuticals business in Germany

02-Nov-2004 - Darmstadt - Merck KGaA has restructured its pharmaceuticals business in Germany. The business with ethicals, which formerly operated as Merck Pharma Germany as a part of Merck KGaA, has been transferred into a legally self-standing company as of November 1, 2004. The new Merck Pharma GmbH ...

Merck KGaA: Intention to close Lacassagne R&D and production site in Lyon, France

Pre-clinical research in France to be concentrated in Chilly-Mazarin

11-Jul-2003 - Merck KGaA announced today that it has decided to launch a project to restructure its pharmaceutical activities in France, including the closure of its Lacassagne research and development (R&D) and production site in Lyon. The project has been presented to employee representatives, local ...

Merck announces R&D restructuring after the decision to discontinue the diabetes projekt

02-Jun-2003 - In a strategic move to focus clinical development resources even more strongly on its Oncology pipeline, Merck KGaA announced today that the company has decided to discontinue further development of two early-stage Diabetes projects. The decision involves EML 16336, an insulin mimetic that ...

Merck KGaA Selects Forest Laboratories As U.S. Partner For Alcohol Addiction Treatment

24-Oct-2001 - Merck KGaA today announced that is has selected Forest Laboratories, Inc. (NYSE: FRX) as its U.S. partner for future marketing and distribution of acamprosate in the United States. A drug for the treatment of alcohol addiction, acamprosate has been approved in most major European markets as well ...